Welcome to our dedicated page for LEMAITRE VASCULAR SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LEMAITRE VASCULAR's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LEMAITRE VASCULAR's regulatory disclosures and financial reporting.
LeMaitre Vascular senior vice president Trent G. Kamke reported multiple equity transactions. On February 27, 2026, he completed an open-market sale of 1,044 shares of common stock at $110.29 per share, after which he directly held 6,677 common shares.
On February 26, 2026, he acquired 1,051 common shares at no cost from the settlement and partial vesting of a performance share unit award, plus 2 additional shares from related dividend equivalent rights. Also on that date, 93 shares were withheld to cover tax obligations tied to the PSU vesting.
LeMaitre Vascular (LMAT) president and director David B. Roberts reported multiple equity transactions. The largest was an open-market sale of 8,464 shares of common stock at a weighted average price of $106.8003 per share, leaving him with 17,979 shares directly owned after that sale.
On the prior day, he acquired common stock through the vesting and settlement of performance share unit (PSU) awards and related dividend equivalent rights, including grants of 1,514 shares and 146 shares at no cost, plus small amounts from dividend equivalents. The company also withheld 134 shares and 13 shares to cover tax obligations upon PSU vesting, which are reported as exempt dispositions.
LEMAITRE VASCULAR INC Chairman and CEO George W. LeMaitre reported a mix of stock sales, awards, and transfers. He sold an aggregate 205,930 shares of common stock in open-market transactions on February 26, 2026 and March 2, 2026, at weighted average prices of $106.7557 and $107.8137 per share, including sales made under a Rule 10b5-1(c) trading plan adopted on March 10, 2025.
On February 26, 2026, he received 5,609 shares upon settlement of a performance share unit award, plus 13 shares from related dividend equivalent rights, and 13 additional common shares from a derivative conversion. The company withheld 496 shares to cover tax obligations on the vesting PSUs.
On March 2, 2026, he made a bona fide gift transfer of 5,000 common shares. Separately, 33,400 shares are held by an irrevocable trust for the benefit of his children, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
LeMaitre (LMAT) reported an insider sale. The filing shows George W. LeMaitre sold 150,000 shares of common stock on 02/26/2026 for $16,013,350.00.
The Form 144 lists securities-to-be-sold entries and prior issuer-side grants and exercises; timing and other quantities are included in the filing.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice to sell Common shares of LMAT tied to restricted stock vesting under a registered plan.
The excerpt lists vesting entries and amounts by date, including 208 shares on 12/11/2024, 182 shares on 12/08/2024, 428 shares on 12/12/2024, 116 shares on 12/20/2024, and 110 shares on 12/02/2024.
LeMaitre Vascular describes a growing, acquisition‑driven vascular device and tissue business with expanding global reach and regulatory complexity. The company sells peripheral vascular devices and human tissue cryopreservation services, focused on vascular surgeons and, increasingly, cardiac surgeons.
LeMaitre estimates the peripheral vascular device market exceeds $9 billion, with about $1 billion addressable by its products. In 2025, roughly 95% of net sales came from territories served by its 160‑person direct sales force, and no single product type exceeded 20% of revenue. Biologic products, including XenoSure, CardioCel, VascuCel, Omniflow II, Artegraft and RestoreFlow allografts, represented 53% of 2025 sales.
The company has completed 25 acquisitions since inception and continues to relocate most manufacturing to its Burlington, Massachusetts headquarters, while maintaining specialized facilities in New Jersey and Illinois. Recent initiatives include MDR and UKCA recertifications, CE marking for Artegraft, expansion of allograft cleanroom capacity, and a new Dublin distribution center to support European tissue sales. LeMaitre also discloses an FDA warning letter at its North Brunswick facility and a January 2026 cybersecurity incident it believes has not had a material financial impact, both highlighted as key risk factors.
LeMaitre Vascular reported strong Q4 2025 and full-year 2025 results while boosting shareholder returns and offering upbeat 2026 guidance. Q4 net sales reached $64.5m, up from $55.7m, with grafts, valvulotomes, and carotid shunts driving 16% sales growth and a gross margin of 71.7%.
Q4 operating income rose to $18.8m, up 47%, and full-year net sales increased to $249.6m from $219.9m. Full-year net income grew to $57.7m, with diluted EPS rising to $2.52 from $1.93, reflecting solid operating leverage.
The board raised the quarterly dividend by 25% to $0.25 per share, payable on March 26, 2026, and authorized a share repurchase program of up to $100m through February 18, 2027. For 2026, the company guides to mid-point sales of $280m (about 12% growth) and operating income of $77.8m, with projected diluted EPS of $2.91.